These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37 related articles for article (PubMed ID: 946596)
1. Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma. Hatschek T; Baldetorp L; Carstensen J; Håkansson L; Möller T; Nilsson B; Termander B Med Oncol Tumor Pharmacother; 1993; 10(4):159-66. PubMed ID: 8164452 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. Gandara DR; Ries CA; Schiff SA; George CB; Lewis JP; Koretz MM; Carter SK Cancer Chemother Pharmacol; 1982; 9(1):10-2. PubMed ID: 7139848 [TBL] [Abstract][Full Text] [Related]
3. Disposition of orally administered 14C-prednimustine in cancer patients. Gaver RC; Deeb G; Pittman KA; Issell BF; Mittelman A; Smyth RD Cancer Chemother Pharmacol; 1983; 11(3):139-43. PubMed ID: 6640823 [TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria. Gandara DR; George CB; Ries CA; Koretz MM; Lewis JP Cancer Chemother Pharmacol; 1987; 19(2):165-8. PubMed ID: 3568275 [TBL] [Abstract][Full Text] [Related]
5. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799 [TBL] [Abstract][Full Text] [Related]
6. Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. Musch E; Malek M; Peter-Katalinic J; Egge H; Rink H; Lathan B; Riedel E Cancer Chemother Pharmacol; 1992; 29(4):297-304. PubMed ID: 1537076 [TBL] [Abstract][Full Text] [Related]
7. Prednimustine in adult acute myeloid leukaemia. Brandt L; Könyves I Cancer Chemother Pharmacol; 1979; 2(2):133-6. PubMed ID: 394873 [TBL] [Abstract][Full Text] [Related]
8. New cancer chemotherapy drugs in Europe. Mathé G; van Putten LM Cancer Chemother Pharmacol; 1978; 1(1):5-13. PubMed ID: 373907 [No Abstract] [Full Text] [Related]
10. [Current status of cytostatic therapy]. Wilmanns W Wien Med Wochenschr; 1974 Nov; 124(48):699-707. PubMed ID: 4611049 [No Abstract] [Full Text] [Related]
11. Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Kaufman JH; Hanjura GL; Mittelman A; Aungst CW; Murphy GP Cancer Treat Rep; 1976 Mar; 60(3):277-9. PubMed ID: 946596 [No Abstract] [Full Text] [Related]
12. Drug essentials. An alkylating agent for CLL and NHL. Wilkes GM Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):55-6. PubMed ID: 19856600 [No Abstract] [Full Text] [Related]
13. Azetepa--a new alkylating agent. McLean JA Isr J Med Sci; 1965 Jul; 1(4):805-7. PubMed ID: 5323047 [No Abstract] [Full Text] [Related]
14. [Therapy of chronic lymphocytic leukemia]. Marmont A Haematol Lat; 1969; 12(3):711-42. PubMed ID: 4097256 [No Abstract] [Full Text] [Related]
15. The management of generalized lymphosarcomatous disease. Cridland MD; Green D Med J Aust; 1968 Aug; 2(5):195-201. PubMed ID: 4877636 [No Abstract] [Full Text] [Related]